-+ 0.00%
-+ 0.00%
-+ 0.00%

ENVISAGENICS AND BOEHRINGER INGELHEIM ENTER MULTI-TARGET COLLABORATION TO DEVELOP FIRST-IN-CLASS PRECISION THERAPIES BASED ON RNA SPLICING-DERIVED TARGETS FOR HARD-TO-TREAT CANCERS

路透·09/22/2026 12:05:36

登录查看新闻详情